No category of advisor is set up to produce the Operational QoE

Every dental M&A transaction has a financial quality of earnings but the operational layer underneath it has never been built into the diligence stack.

Financial QoE firms know audit and accounting. Dental consulting firms know operations and they help owners run better practices over months and years, but they don't produce forensic documentation of the gap between earned and capturable revenue for a transaction event. Brokers facilitate transactions, but forensic operational reviews on every listing is not in scope. Internal operators run the business yet rarely produce buyer-grade documentation about their own performance gaps, for obvious reasons.

No category of advisor is set up to produce the Operational QoE. It's a structural absence. So the work of documenting that operational layer does not get done. Buyers underwrite without it, close the acquisition, and discover the true operational picture themselves months later when their integration team opens the PMS. Lapsed recall, unscheduled treatment, provider production variance, no-show patterns, retention curves that bleed value over 18 months. All of it has been sitting in the software the entire time, but by the time the buyer's team finds it the purchase price is fixed and the discovery becomes a value creation problem instead of a transaction input. The seller left it on the table, and the buyer absorbs it as integration work. Everyone moves on and the cycle repeats on the next deal.

This was tolerable when dental PE was running on multiple arbitrage. Buy at 5x, roll into a platform, exit at 12x, and the operational layer inside each tuck-in worked itself out at the platform level. The arbitrage was the return and the diligence stack was built around that thesis.

But we all know that thesis is breaking. More than 40 DSOs were brought to market in the past two years and less than 10 closed. Hold periods stretched from 3 to 5 years out to 5 to 7 plus because operational reality at each tuck-in did not match what was sold and the problems compounded platform-level. Sellers used to get 100% cash at close, now they get 65 to 70% with the rest in holdback tied to operational performance. Entry multiples crept up, lender leverage came down, and LP pressure on PE returns is rising. The exit math no longer survives operational surprise.

That's why the next wave of buyers cannot rely on the old underwriting model. The return cannot come from rolling the asset into a bigger platform exit, because that exit math no longer works. It has to come from running the specific practice better than the seller did, which means the buyer needs to know what the practice is actually doing today, before they sign the LOI.

Financial QoE cannot answer that question, and neither can anything else in the current diligence stack. Our Operational QoE is the piece of diligence that does. It quantifies the opportunity: what the practice should be earning, with patient-level evidence the buyer's own ops team can validate.